Posted by Michael Wonder on 25 Feb 2022
PBAC recommendation for molnupiravir (Lagevrio)
25 February 2022 - The PBAC undertook an expedited consideration of a sponsor submission (MSD) to add molnupiravir (Lagevrio) to the PBS for use in treating patients with mild to moderate COVID-19 who are at risk of developing severe disease requiring hospitalisation.
The expedited consideration by PBAC recognises the urgent public health need related to the prevention, management, or treatment of SARS-CoV-2 infections.
A very interesting development. When was the submission lodged? Was the submission fully evaluated? No news on when Lagevrio will be listed on the PBS.
